Collectively, these results position compound 15 as a VEGFR–2–targeted breast cancer lead that combines potent cytotoxicity with apoptosis induction and angiogenesis blockade, while compound 14 emerges as a complementary VEGFR-2-focused chemotype with encouraging pharmacokinetic prospects warranting in vivo exploration [36,58,59,60]. The gene discussed is KDR; the disease is breast cancer.